Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jan 16.

Published in final edited form as: J Neurochem. 2010 Aug 25;115(2):325–332. doi: 10.1111/j.1471-4159.2010.06922.x

Fig. 1 — A “challenge” METH regimen decreases both (A) the velocity and magnitude of K⁺-stimulated DA release from striatal suspensions and (B) DA content in the VMAT-2M- and VMAT-2C-associated vesicle fractions (B). Rats received four injections of METH (7.5 mg/kg/injection, s.c., 2-h intervals) or saline vehicle (1 ml/kg/injection, s.c., 2-h intervals) and were killed 1 h later. Columns represent the mean ± 1 S.E.M. of 6 to 8 independent determinations. *, indicates a statistical difference between saline- and METH-treated animals.

Fig. 1 — A “challenge” METH regimen decreases both (A) the velocity and magnitude of K⁺-stimulated DA release from striatal suspensions and (B) DA content in the VMAT-2M- and VMAT-2C-associated vesicle fractions (B). Rats received four injections of METH (7.5 mg/kg/injection, s.c., 2-h intervals) or saline vehicle (1 ml/kg/injection, s.c., 2-h intervals) and were killed 1 h later. Columns represent the mean ± 1 S.E.M. of 6 to 8 independent determinations. *, indicates a statistical difference between saline- and METH-treated animals.